Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US biopharmaceutical company Ziopharm Oncology has begun dosing of the first patient in a phase II trial of its investigational drug for the treatment of patients with primary liver cancer.
Subscribe to our email newsletter
Primary liver cancer is one of the most commonly occurring cancers in the world. The study will take place at five major US liver cancer treatment centers including sites in New York, Boston, Miami, Seattle, and Atlanta.
Brian Schwartz, chief medical officer at Ziopharm, said: “Liver cancer is one of the most difficult cancers to manage. We look forward to seeing if this novel form of organic arsenical will give clinicians an additional treatment option.”
In addition to the phase II liver cancer trial, the company is conducting phase II studies with ZIO-101 in advanced multiple myeloma and diverse hematological cancers, including acute myelogenous leukemia, myelodysplastic syndrome and acute promyelocytic leukemia.